News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
363,472 Results
Type
Article (14425)
Company Profile (115)
Press Release (348932)
Section
Business (112660)
Career Advice (456)
Deals (18621)
Drug Delivery (28)
Drug Development (31205)
Employer Resources (50)
FDA (8795)
Job Trends (7685)
News (172828)
Policy (12369)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (6)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (1318)
Allergies (36)
Alliances (34764)
ALS (21)
Alzheimer's disease (494)
Antibody-drug conjugate (ADC) (54)
Approvals (8804)
Artificial intelligence (217)
Autoimmune disease (1)
Automation (11)
Bankruptcy (131)
Best Places to Work (6535)
BIOSECURE Act (6)
Biosimilars (9)
Biotechnology (88)
Bladder cancer (20)
Brain cancer (11)
Breast cancer (103)
Cancer (880)
Cardiovascular disease (56)
Career advice (406)
Career pathing (8)
CAR-T (92)
Cell therapy (246)
Cervical cancer (7)
Clinical research (24395)
Collaboration (534)
Compensation (98)
Complete response letters (3)
COVID-19 (1145)
CRISPR (34)
C-suite (117)
Cystic fibrosis (47)
Data (828)
Decentralized trials (1)
Denatured (18)
Depression (14)
Diabetes (84)
Diagnostics (4884)
Digital health (15)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (69)
Drug pricing (13)
Drug shortages (4)
Duchenne muscular dystrophy (16)
Earnings (38427)
Editorial (2)
Employer branding (8)
Employer resources (43)
Events (51015)
Executive appointments (345)
FDA (9317)
Featured Employer (26)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (422)
Gene editing (78)
Generative AI (23)
Gene therapy (155)
GLP-1 (213)
Government (1232)
Grass and pollen (1)
Guidances (23)
Healthcare (9887)
Huntington's disease (5)
IgA nephropathy (8)
Immunology and inflammation (24)
Indications (9)
Infectious disease (1213)
Inflammatory bowel disease (57)
Inflation Reduction Act (3)
Influenza (30)
Intellectual property (47)
Interviews (51)
IPO (8009)
IRA (8)
Job creations (1434)
Job search strategy (362)
Kidney cancer (3)
Labor market (9)
Layoffs (114)
Leadership (3)
Legal (2524)
Liver cancer (34)
Lung cancer (112)
Lymphoma (55)
Machine learning (2)
Management (17)
Manufacturing (159)
MASH (14)
Medical device (11430)
Medtech (11435)
Mergers & acquisitions (10907)
Metabolic disorders (188)
Multiple sclerosis (23)
NASH (3)
Neurodegenerative disease (23)
Neuropsychiatric disorders (2)
Neuroscience (661)
NextGen: Class of 2025 (3537)
Non-profit (1519)
Northern California (970)
Now hiring (8)
Obesity (83)
Opinion (76)
Ovarian cancer (32)
Pain (43)
Pancreatic cancer (35)
Parkinson's disease (59)
Partnered (9)
Patents (117)
Patient recruitment (46)
Peanut (25)
People (32625)
Pharmaceutical (16)
Phase I (9003)
Phase II (11023)
Phase III (7130)
Pipeline (394)
Podcasts (36)
Policy (26)
Postmarket research (502)
Preclinical (4042)
Press Release (66)
Prostate cancer (36)
Psychedelics (4)
Radiopharmaceuticals (154)
Rare diseases (128)
Real estate (3358)
Recruiting (20)
Regulatory (9300)
Reports (18)
Research institute (1268)
Resumes & cover letters (68)
Rett syndrome (2)
RNA editing (1)
RSV (20)
Schizophrenia (11)
Series A (78)
Series B (46)
Service/supplier (7)
Sickle cell disease (16)
Southern California (1045)
Special edition (1)
Sponsored (13)
Startups (2504)
State (2)
Stomach cancer (1)
Supply chain (21)
The Weekly (17)
United States (10250)
Vaccines (298)
Venture capitalists (18)
Webinars (7)
Weight loss (34)
Women's health (16)
Worklife (2)
Date
Today (10)
Last 7 days (296)
Last 30 days (1469)
Last 365 days (17915)
2025 (3423)
2024 (18718)
2023 (22102)
2022 (30838)
2021 (32538)
2020 (30559)
2019 (25809)
2018 (19471)
2017 (18881)
2016 (17766)
2015 (20567)
2014 (15180)
2013 (12744)
2012 (13786)
2011 (14071)
2010 (12827)
Location
Africa (319)
Alabama (36)
Alaska (6)
Arizona (112)
Arkansas (9)
Asia (23940)
Australia (4168)
California (2534)
Canada (954)
China (205)
Colorado (149)
Connecticut (124)
Delaware (36)
Europe (48924)
Florida (420)
Georgia (122)
Idaho (33)
Illinois (250)
India (10)
Indiana (149)
Iowa (4)
Japan (92)
Kansas (79)
Kentucky (6)
Louisiana (5)
Maine (20)
Maryland (422)
Massachusetts (1789)
Michigan (176)
Minnesota (229)
Mississippi (2)
Missouri (54)
Montana (24)
Nebraska (15)
Nevada (19)
New Hampshire (65)
New Jersey (795)
New Mexico (16)
New York (747)
North Carolina (488)
North Dakota (7)
Northern California (970)
Ohio (96)
Oklahoma (10)
Oregon (19)
Pennsylvania (518)
Puerto Rico (5)
Rhode Island (18)
South America (505)
South Carolina (14)
South Dakota (1)
Southern California (1045)
Tennessee (53)
Texas (407)
Utah (94)
Virginia (52)
Washington D.C. (10)
Washington State (299)
West Virginia (3)
Wisconsin (33)
363,472 Results for "zenith technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Zenith Capital Corp. Provides Update on the Company’s Upcoming Annual General Meeting
December 16, 2024
·
5 min read
Zenith Epigenetics Proudly Supports Rare Disease Day
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694
February 29, 2024
·
5 min read
Pharm Country
West Introduces Daikyo Crystal Zenith® (CZ) Ready-to-Use Nested Vials in Tub at the International Society for Cell and Gene Therapy
West Pharmaceutical Services, Inc. announced that it will unveil its new Daikyo Crystal Zenith® Nested Vials in Tub at the International Society for Cell and Gene Therapy Annual Meeting taking place in Vancouver, Canada from May 29- June 1.
May 29, 2024
·
2 min read
Press Releases
Medline receives AARC’s 2024 Zenith Award for dedication to respiratory care
October 2, 2024
·
2 min read
Press Releases
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
November 25, 2024
·
9 min read
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics’ ZEN-3694 program.
October 26, 2023
·
7 min read
Press Releases
Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
September 24, 2024
·
3 min read
Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC). NC is a highly aggressive type of squamous cell cancer with very poor prognosis that often forms in the head, neck, or lungs.
June 1, 2023
·
6 min read
Business
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.
January 31, 2022
·
6 min read
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI sponsored clinical trials for safety and efficacy in multiple oncology indications with significant unmet need, through the NCI’s Cancer Therapy Evaluation Program (CTEP).
July 6, 2022
·
10 min read
1 of 36,348
Next
